just screwed up. >> carry lynn barta, from 19 -- carolyn barta, from 1996 after he lost the second time how involved was ross perot? did he exit from the national stage or did he stay involved? >> pretty much exited, i think. he was not -- not particularly involved in issues or in the reform party after that. i think -- 1992 was really the unique time. because of the -- the sense of alienation that people had with government. the dissatisfaction with government. the economic problems. and then 1996, as you said earlier, when things started to come back, the political climate didn't exist anymore. and he did not -- he wanted the people to stay active. and involved. but the climate didn't exist for the kind of perot phenomenon to happen again as it did in 1992. and i think that was sort of his swan song. he got out after that. >> sacramento, hello, to jason as we talk about ross perot. you're on. >> yeah. i just want to ask, how do you feel perot would do in the 2013 election currently if he was on the same wavelength that he was on in 1992? and another question, if you don't mind, was i

kadlec, we did not appropriate to warp speed, we appropriated money to the partners, nih and barta, my understanding is at least $16 billion has come through those agencies for the vaccine up until now. hhs has told us that to have 300 million copies of vaccine available, they need another $20 billion that they don't have in any specifically appropriated line. do you agree with that number? >> sir, based on current situation, yes, that seems to be the number. >> all right. dr. redfield, the plans you expect to get back from the states by november 1 on distribution of the vaccine, do you think you'll be ready shortly after that to announce your final distribution plan for vaccine? >> senator, it is going to be dependent on the advisory committee of immunization practices which will make the final recommendation for prioritization. >> i think i'm asking another question. maybe i didn't ask it well. i want to talk about that, too. but surely prioritization will not impact how you send this out to the states. it might impact the number they get. but in terms of the protection of the vaccin

some from the nih and some from barta. we sit around the table and if there is oninvestment opportunity we do it, and if there's an acquisition opportunity like buying 150 million of the buy next tests we did that. we announced a $760 million deal the day after the all theization. that didn't happen by random. this has been planned for over a month to -- to do that to buy it and to distribute did in a way that supports reopening. >> there's a lot of sort of stories of people wanting tests but not being able to get tested, and it does raise this question, which has come up as well, is who should get tested? when should they get tested? recently guideline changes were made at the cdc saying people without symptoms, asymptomatic people do not necessarily need to be tested? that should be left up to public health officials in that particular area, but that's confusing i think to me and to a lot of people because we know so much of the spread of this virus in this country comes from people who don't have symptoms or don't yet h

that's what this administration has done through barta the last few years. this isn't like some of the p.p.e. we have to outsource overseas. we have the ability to create hundreds of millions of vaccines and we likely will by next year. again,s have very, very unusual. this is -- as you'll hear from a lot of the docs tonight, this is very unusual. to be able to do this within months, to be able to tell the american people that there is light at the end of the tunnel, that we see the end of this pandemic because, and again, as the american people know, your own local cool brd may have said you know what, we can't go back to school full time until there's a vaccine. ladies and gentlemen, we're going to have that vaccine. we're going to have it because this administration is -- has cut through the red tape with operation warp speed assuring a safe,esquive vaccine that can be produced for hundreds of millions of people. that's really phenomenal. once we take care of the united states, we can actually take care of the world and help end this pandemic. that'll be

. >> del hospital salÍ con una bata, una barta verde del hospital. me subieron a la patrulla.niÑos que fueron deportados. intentÓ regresar al campamento migrante donde pasÓ casi 7 meses. pero las autoridades mexicanas no la aceptaron. finalmente sandra y su familia vivieron temporalmente en la vecindad, el tiempo se acaba y en los prÓximos dÍas no tendrÁn dÓnde ir. >> no sabemos ni quÉ va a ser de nosotros. estoy ahora sÍ a las manos de dios. jorge: sobre la historia la patrulla fronteriza dijo " los ciudadanos estadounidenses no pueden ser deportados si una madre no tiene derecho de estar en estados unidos, si tiene un hijo estadounidense no serÁ deportado, acompaÑrÁ a la madre donde sea que ella regrese" . vamos con fÉlix y un adelanto de esta noche. >> muchas gracias. tenemos un nuevo informe del congreso de estados unidos que denuncia la muerte de inmigrantes en centros de detenciÓn como consecuencia de tratamientos mÉdicos inadecuados, negligencia o por el retraso a la hora de recibir esos cuidados sanitarios. una cÁmara de seguridad capta el momento exacto en que un suje

public-private collaboration around new therapies and veryy importantly vaccines in the support from barta has been invaluable to the pharma companies that are developing the vaccines and we presume there's going to be ample payoff in terms of effective vaccine. there have been other areas where the response has not been robust and mixed and we don't have any real national covid testing strategy for example but there is been sporadic leadership on areas like the supply chain. if we were resetting the clock on the pandemic, what do you think should have done differently in terms of the federal response. >> susan, i have to respectfully beg to differ on the characterizations there has been a national testing strategy coronavirus.gov i read it regularly, it is right there and we are following thatol testing strategy and we have 92 million tests that are been performed, capacity for 3 million teston pr day, were doing 820,000 test per day and we have rapid point-of-care and antibody pcr and rapid antigenic pcr testing to point-of-care and speeds that nobody thought were even possible when we b

we've seen a tremendous blending of programs at nih, cdc, barta, in my office with the defense production act. all coming together and we do meet every week to put these together in a very synergistic way. yes. in october, and again, these are conservative mats based on what we know as euas and what we know the manufacturing will be. in october, we're looking at somewhere in the neighborhood of 125 to 135 million tests available. that doesn't mean they'll be done. but these will be easily and readily available and the majority of them, we really hit that inflection point, will be point of care. >> good. >> mf of thep will be the buy next that we talked about. that will be made at approximately 48 to 50 million per month. again, $5 tests. 15-minute result. no instrument. very, very important. but we're starting to see the point of care coming from the shark tank, really hit iting th streets, so the next generation sequencing. the micro fluidics like fluidime and some advanced point of care are all starting to hit from shark tank. >> and i think you said in your testimony that sometime this

since early 2020 asper and barta worked-earth to forward vaccine development. a whole of government approach working with our private sector partners to produce and deliver a safe and effective vaccine asfast as possible. the supplemental appropriations provided by this committee have been essential in permitting significant advancements under warp speed. as a result america is far better positioned than before to keep america safe, protect vulnerable communities and individuals and defeat the covid-19 virus. to date we've awarded $13.6 billion to support over 50 medical counter measure projects. some of these awards are vaccine contracts. we're making significant progress in advancing these vaccines through clinical trial process. in fact, three candidates are in phase three clinical trials meaning that we're closer than ever to a safe and effective vaccine available to the public. three others are in phase one and two. safety is our top priority in the development of vaccines and therapeutics which is why science is driving the development of all covid-19 cou

what has happened, john, that many people don't realized is the government through barta has invested hundred of millions in creating and having the vaccines being tested being manufactured so they are being manufactured so if any other vaccines -- let's say vaccine "a" is approved they can go and pull 100 million doses of vaccine "a" instead of waiting for approval and production, production is already happening so they are both right. however, the reality is the -- the logistics of getting this vaccine to millions of people, the logistics because most likely you need two dose and you need two doses and refrigeration, and add miller giroir is right. to get the millions of doses to millions of people is probably not going to be feasible until mid-2021. >> thank you, sir. >> thank you, john. >>> breaking news just into us. justice ruth bader ginsburg will lie in repose at the supreme court on wednesday and thursday of this week. more now on this breaking news. joan, this was a question. yes, of course, there's tradition, but then there's also this pandemic. >> that's right. and in the

presidents were visionary in this respect -- they built those stand-by manufacturing plants, they created barta. senator burr from north carolina was one of the leaders for that, for example. and without that, we wouldn't have this explosion of vaccines, treatments, and tests on the way. we need to do that again. senator bill frist, the former majority leader, testified before our committee with some others. he said we go from panic to neglect to panic. and we don't do the hard things to do after the epidemic is over. the hardest thing to do is sustained ling -- sustained funding. we need sustained funding for manufacturing plants so they don't go cold while we wait for the next pandemic. we need sustained funding for our stockpile so they're not depleted by budget problems. we need sustained funding for the strategic stockpile. and we need sustained funding for our state and local public health agencies which are about 50% supported by federal dollars. sustained funding is something we don't do very well. that means mandatory funding. it means advanced appropriations. we like to do it year by

barta was able to announce awards for potential covid-19 treatment of vaccine candidates just over one month after the vaccine was first reported in china. as i said earlier four of the first six vaccines are being manufactured in facilities built in 2012 for this purpose, for a future pandemic. and then there's been federal support over the years for state, local and hospital preparedness. $21 billion between 2002 and 2017. cdc has used existing programs to help states retrain work forces, expand lab capacity, planning for a future pandemic from pandemics during the last several years. and even with super computing, these congresses, the last few have increased funding in the department of energy so that the united states is first in the world in super computing. they're in our national laboratories and they're being used to help develop treatments and vaccines. so i go through all of that to show that several congresses and several presidents have done things to help us get ready towards this unprecedented sprint towards vaccines, treatments and tests. and finally i'd like for this c

i appreciate you raising the background and senator, your role in getting barta to where it is right now has been critical for operation warp speed and doing things in a business friendly way to get the tools we need in place. the other thing i had the privilege of helping make happen in late march/april, was to go to the pharmaceutical companies we knew had something to offer; instead of saying, let's go off in our own direction, let's see if we can do something together. active came about. 24/7, 100 people, mostly high-ranking scientists in public/private sector designed protocols to launch trials without the process it come and out of that have series of trials on antibodies, anticoagulant, immunomodulators. .hat has gotten us much further emboldened by the scientific community. you have the statute to do that? dr. collins: it helps that no one was feeling, we have to do six months of consultation. we see the u.s. government functioning. [indiscernible] we have not changed the rules or protocols. we have exercised latitude in statute for incidents like this. admiral, one question.